MurphySLXuJQKochanekKD. Deaths: final data for 2010. Natl Vital Stat Rep. 2013;61(4).
2.
StoneNJRobinsonJLichtensteinAH. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934.
3.
JacobsonTAItoMKMakiKC. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary. J Clin Lipidol. 2014;8(5):473-488.
4.
American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2016;39(suppl. 1):S60-S71.
5.
GarberAJAbrahamsonMJBarzilayJI. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2016 executive summary. Endocr Pract. 2016;22:84-113.
6.
RidkerPMPradhanAMacFadyenJG. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565-571.
7.
BoekholdtSMHovinghGKMoraS. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64:485-494.
8.
GinsbergHNElamMBLovatoLC.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
9.
BodenWEProbstfieldJLAndersonT.; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267.
10.
HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in 25,673 high-risk individuals receiving statin-based therapy: the HPS2-THRIVE randomized placebo-controlled trial. N Engl J Med. 2014;371:203-212.
11.
KasteleinJPAkdimFStroesESG. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431-1443.
12.
CannonCPBlazingMAGiuglianoRP; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397.
13.
McKenneyJM. Understanding PCSK9 and anti-PCSK9 therapies. J Clin Lipidol. 2015;9(2):170-186.
